BenchSci founders, clockwise from top left: Liran Belenzon, Elvis Wianda, David Chen and Tom Leung

F-Prime backs a niche AI soft­ware start­up hunt­ing lofty goals in $22M Se­ries B

For many of the AI com­pa­nies sprout­ing on the bio­phar­ma field, val­i­da­tion — of­ten mean­ing con­fir­ma­tion of whether the tar­gets and drugs they iden­ti­fied or gen­er­at­ed would ac­tu­al­ly work — won’t come in years, if at all. But for Bench­Sci, the drug hunt­ing field is their home turf.

To be sure, the Toron­to-based start­up is do­ing some­thing very dif­fer­ent from the rest of the pack. Rather than stak­ing claims about the re­sults of drug dis­cov­ery, it’s out to change the process by hun­ker­ing down on a spe­cif­ic prob­lem: help­ing sci­en­tists se­lect the right reagents to con­duct their pre­clin­i­cal ex­per­i­ments.

Hav­ing start­ed out with an an­ti­body se­lec­tion ser­vice 18 months ago, Bench­Sci is now ready to roll out a broad­er reagent se­lec­tion plat­form and ex­pand the clien­tele from aca­d­e­m­ic in­sti­tu­tions and Big Phar­ma to biotechs — thanks to a $22 mil­lion cash in­jec­tion.

In con­trast with the clin­i­cal or com­mer­cial realm, Bench­Sci found that its chal­lenge wasn’t to com­pete with ri­val ven­dors but to con­vince in­vestors that there’s a mar­ket, CEO Li­ran Be­len­zon told End­points News.

“There is no soft­ware com­pa­ny in pre­clin­i­cal,” he said, leav­ing sci­en­tists to work on soft­ware with in­ter­faces that “look like they’re from the 1990s.”

But the ex­pe­ri­ence of his co-founder and CSO Tom Le­ung, who saw first hand how an in­ap­pro­pri­ate an­ti­body could cost him rare pa­tient sam­ples and lead to month­long de­lays, and sub­se­quent chats with oth­er re­searchers con­vinced them there’s an op­por­tu­ni­ty here. Col­lat­ing da­ta from open ac­cess jour­nals and ink­ing deals with big name pub­lish­ers like Springer Na­ture, Wi­ley and JA­MA, Bench­Sci came up with a data­base of sci­en­tif­ic lit­er­a­ture that they then teach the com­put­er to read.

“So the sci­en­tist ba­si­cal­ly asks our sys­tem the ques­tion: Out of those 5,000 reagents or an­ti­bod­ies that are out there, which one will work on BR­CA1, in this tis­sue, in this spe­cif­ic cell line, in this mod­el, with this spec­i­fi­ca­tion,” Be­len­zon said, “and we re­al­ly nar­row down these 4 or 5,000 to 2 or 3 and then we say, hey, these are the an­ti­bod­ies most like­ly to work in your ex­per­i­ment, and here’s all the sci­en­tif­ic da­ta and the ex­per­i­men­tal re­sults that this spe­cif­ic reagent has gen­er­at­ed and sci­en­tists can ac­tu­al­ly see those re­sults and val­i­date it as well.”

That means con­dens­ing the whole process of se­lect­ing reagents — tra­di­tion­al­ly done by tri­al and er­ror — from 12 weeks to 30 sec­onds, ac­cord­ing to the com­pa­ny, re­duc­ing waste by 70% and sav­ing mil­lions of dol­lars in hard cost.

It’s not quite shav­ing years and tens of mil­lions off the drug dis­cov­ery process as oth­ers have promised (and many have doubt­ed). Yet Bench­Sci still cites some big num­bers: a $10.2 bil­lion per year op­por­tu­ni­ty for sav­ings on reagents, de­duced from the es­ti­mate that $28 bil­lion each year is wast­ed on ir­re­pro­ducible re­search, with reagents and ref­er­ence ma­te­ri­als ac­count­ing for 36.1%.

F-Prime Cap­i­tal, which led the Se­ries B, and oth­er in­vestors in­clud­ing North­leaf Cap­i­tal Part­ners, Gra­di­ent Ven­tures, In­ovia Cap­i­tal, Gold­en Ven­tures and Re­al Ven­tures would love to see them get there. But will they?

“They would be a per­fect ac­qui­si­tion tar­get for Gene­script, Qi­a­gen, Ther­mo Fish­er, or oth­er an­ti­body and reagent mak­er,” Alex Zha­voronkov, founder and CEO of AI drug dis­cov­ery start­up In­sil­i­co Med­i­cine, wrote to End­points. “With this mod­el they can quick­ly get to sub­stan­tial rev­enue pos­si­bly in tens of mil­lions but the mar­ket size is rather lim­it­ed and it will be dif­fi­cult to grow.”

As he pre­pares to dou­ble the size of his team to 140 to sup­port the growth in­to re­com­bi­nant pro­teins, RNAi, CRISPR, cell lines and more, Be­len­zon sees oth­er­wise.

“To­day in an age where you have AI com­pa­nies gen­er­at­ing more and more and more po­ten­tial­ly great tar­gets to study, there needs to be a com­pa­ny that helps to study those tar­gets faster and bet­ter and cheap­er,” he said. “That’s re­al­ly what we are fo­cus­ing on.”

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Alex­ion puts €65M for­ward to strength­en its po­si­tion on the Emer­ald Isle

Ireland has been on a roll in 2022, with several large pharma companies announcing multimillion-euro projects. Now AstraZeneca’s rare disease outfit Alexion is looking to get in on the action.

Alexion on Friday announced a €65 million ($68.8 million) investment in new and enhanced capabilities across two sites in the country, including at College Park in the Dublin suburb of Blanchardstown and the Monksland Industrial Park in the central Irish town of Athlone, according to the Industrial Development Agency of Ireland.

Members of the G7 from left to right: Prime Minister of Italy Mario Draghi, European Commission President Ursula von der Leyen, President Joe Biden, German Chancellor Olaf Scholz, British Prime Minister Boris Johnson, Canadian Prime Minister Justin Trudeau, Prime Minister of Japan Fumio Kishida, French President Emmanuel Macron and European Council President Charles Michel (AP Photo/Susan Walsh)

Biden and G7 na­tions of­fer funds for vac­cine and med­ical prod­uct man­u­fac­tur­ing project in Sene­gal

Amidst recently broader vaccine manufacturing initiatives from the EU and European companies, the G7 summit in the mountains of Bavaria has brought about some positive news for closing vaccine and medical product manufacturing gaps around the globe.

According to a statement from the White House, the G7 leaders have formally launched the partnership for global infrastructure, PGII. The effort will aim to mobilize hundreds of billions of dollars to deliver infrastructure projects in several sectors including the medical and pharmaceutical manufacturing space.

State bat­tles over mifepri­s­tone ac­cess could tie the FDA to any post-Roe cross­roads

As more than a dozen states are now readying so-called “trigger” laws to kick into effect immediate abortion bans following the overturning of Roe v. Wade on Friday, these laws, in the works for more than a decade in some states, will likely kick off even more legal battles as states seek to restrict the use of prescription drug-based abortions.

Since Friday’s SCOTUS opinion to overturn Americans’ constitutional right to an abortion after almost 50 years, reproductive rights lawyers at Planned Parenthood and other organizations have already challenged these trigger laws in Utah and Louisiana. According to the Guttmacher Institute, other states with trigger laws that could take effect include Arkansas, Idaho, Kentucky, Mississippi, Missouri, North Dakota, Oklahoma, South Dakota, Tennessee, Texas, and Wyoming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Deborah Dunsire, Lundbeck CEO

Af­ter a 5-year re­peat PhI­II so­journ, Lund­beck and Ot­su­ka say they're fi­nal­ly ready to pur­sue OK to use Rex­ul­ti against Alzheimer's ag­i­ta­tion

Five years after Lundbeck and their longtime collaborators at Otsuka turned up a mixed set of Phase III data for Rexulti as a treatment for Alzheimer’s dementia-related agitation, they’ve come through with a new pivotal trial success they believe will finally put them on the road to an approval at the FDA. And if they’re right, some analysts believe they’re a short step away from adding more than $500 million in annual sales for the drug, already approved in depression and schizophrenia.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

A Mer­ck part­ner is sucked in­to the fi­nan­cial quag­mire as key lender calls in a note

Another biotech standing on shaky financial legs has fallen victim to the bears.

Merck partner 4D Pharma has reported that a key lender, Oxford Finance, shoved the UK company into administration after calling in a $14 million loan they couldn’t immediately make good on. Trading in their stock was halted with a market cap that had fallen to a mere £30 million.

“Despite the very difficult prevailing market conditions,” 4D reported on Friday, the biotech had been making progress on finding some new financing and turned to Oxford with an alternative late on Thursday and then again Friday morning.

Fed­er­al judge de­nies Bris­tol My­er­s' at­tempt to avoid Cel­gene share­hold­er law­suit

Some Celgene shareholders aren’t happy with how Bristol Myers Squibb’s takeover went down.

On Friday, a New York federal judge ruled that they have a case against the pharma giant, denying a request to dismiss allegations that it purposely slow-rolled Breyanzi’s approval to avoid paying out $6.4 billion in contingent value rights (CVR).

When Bristol Myers put down $74 billion to scoop up Celgene back in 2019, liso-cel — the CAR-T lymphoma treatment now marketed as Breyanzi — was supposedly one of the centerpieces of the deal. After going back and forth on negotiations for about six months, BMS put $6.4 billion into a CVR agreement that required an FDA approval for Zeposia, Breyanzi and Abecma, each by an established date.

Chris Anzalone, Arrowhead CEO

Take­da, Ar­row­head spot­light da­ta from small tri­al show­ing RNAi works in a rare liv­er con­di­tion

Almost two years after Takeda wagered $300 million cash to partner with Arrowhead on an RNAi therapy for a rare disease, the companies are spelling out Phase II data that they believe put them one step closer to their big dreams.

In a small, open label study involving only 16 patients who had liver disease associated with alpha-1 antitrypsin deficiency (AATD), Arrowhead’s candidate — fazirsiran, previously ARO-AAT — spurred substantial reductions in accumulated mutant AAT protein in the liver, a hallmark of the condition. Investigators also tracked improvements in symptoms, with seven out of 12 who received the high, 200 mg dose seeing regression of liver fibrosis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

No stranger to gene ther­a­py woes, Astel­las runs in­to an­oth­er safe­ty-re­lat­ed clin­i­cal hold

Astellas Pharma, which has been at the forefront of uncovering the risks associated with gene therapies delivered by adeno-associated viruses, must take another safety alarm head-on.

The FDA has slapped a clinical hold on Astellas’ Phase I/II trial of a gene therapy candidate for late-onset Pompe disease, after investigators flagged a serious case of peripheral sensory neuropathy.

It marks the latest in a streak of setbacks Astellas has encountered since making a splashy entry into the gene therapy space with its $3 billion buyout of Audentes. But the lead program, AT132 for the treatment of X-linked myotubular myopathy (XLMTM), had to be halted more than once after a total of four patients died in the trial — and the scientific community still doesn’t have all the answers of what caused the deaths.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.